Skip to main content

Table 4 Changes in biomarker levels in the study groups

From: Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)

Variables Group A (Atorvastatin) Group B (Aspirin) Group C (Both) Group D (None) P Value
CRP (mg/dl)
 Pre 1.05 (0.25–3.65) 1.36 (0.20–6.72) 0.95 (0.18–4.74) 1.05 (0.23–4.48)  
 Post 0.59 (0.13–1.60) 0.60 (0.16–1.77) 0.49 (0.09–1.59) 0.61 (0.13–2.34)  
Percentage (%) change
   Per protocol − 49.71 (− 81.98–3.50) − 53.81 (− 84.73–9.09) − 54.77 (− 82.76–29.22) − 44.73 (− 81.22–14.09) 0.89
   As per treatment received − 51.56 (− 82.14–4.85) − 54.84 (− 84.73–8.10) − 55.41 (− 83.59–28.60) − 62.59 (− 84.77–4.12) 0.86
IL-6 (pg/mL)
 Pre 4.95 (1.35–17.45) 5 (1.3–20.6) 6.15 (1.2–27.0) 4.9 (1.2–13)  
 Post 2.7 (0.75–8.7) 2.8 (0.8–9.6) 2.25 (0.7–6.4) 3.3 (1.2–10.9)  
Percentage (%) change
   Per protocol − 27.83 (− 78.91–98.21) − 40.42 (− 79.86–71.42) − 53.46 (− 84.29–23.21) 0 (− 66.79–142.46) 0.007
   As per treatment received − 27.83 (− 79.71–98.21) − 40.42 (− 79.86–71.42) − 51.54 (− 83.08–23.21) − 16.66 (− 72–120) 0.08
Trop I (ng/mL)
 Pre 0.006 (0.001–0.007) 0.005 (0.001–0.01) 0.006 (0.001–0.01) 0.005 (0.001–0.007)  
 Post 0.004 (0.001–0.006) 0.005 (0.001–0.008) 0.004 (0.001–0.006) 0.003 (0.001–0.006)  
Percentage (%) change
   Per protocol − 11.98 (− 83.33–40) 0 (− 83.33–50) − 33.33 (− 83.33–0) 0 (− 83.33–50) 0.55
   As per treatment received − 16.66 (− 83.33–40) 0 (− 83.33–40) − 34.52 (− 83.33–0) − 24.03 (− 83.33–50) 0.64
  1. All values are Median (p25-p75); Bold P values are significant
  2. CRP C-reactive protein, IL-6 interleukin 6, Trop I troponin I, IU International Unit, L litre, mg milligram, mL millilitre, pg picogram, ng nanogram
  3. Local lab ranges: CRP ≤ 0.06 mg/dl, IL6 = 0–4.4 pg/ml, Ferritin = 22–322 ng/ml, D-dimer ≤ 500 ng/ml, CPK = 32–294 IU/L and Troponin I ≤ 0.04 ng/ml